Chronic obstructive pulmonary disease (COPD) is associated with acute and chronic pulmonary as well as systemic inflammation [1]. Anti-inflammatory treatments, such as inhaled corticosteroids (ICS) and oral roflumilast, are recommended for COPD patients [2]. These drugs are effective agents for the prevention of COPD exacerbations and improvement of lung function and have various effects on health status, but they are associated with adverse events, the most concerning being pneumonia (ICS) and diarrhoea (roflumilast).
Peripheral eosinophil count as a biomarker for the management of COPD: not there yet / Rabe, Klaus F.; Beghé, Bianca; Fabbri, Leonardo M.. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 50:5(2017), pp. 1-4. [10.1183/13993003.02165-2017]
Peripheral eosinophil count as a biomarker for the management of COPD: not there yet.
Bianca Beghé;Leonardo M. Fabbri
2017
Abstract
Chronic obstructive pulmonary disease (COPD) is associated with acute and chronic pulmonary as well as systemic inflammation [1]. Anti-inflammatory treatments, such as inhaled corticosteroids (ICS) and oral roflumilast, are recommended for COPD patients [2]. These drugs are effective agents for the prevention of COPD exacerbations and improvement of lung function and have various effects on health status, but they are associated with adverse events, the most concerning being pneumonia (ICS) and diarrhoea (roflumilast).
| File | Dimensione | Formato | |
|---|---|---|---|
|
1702165.full.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
325.08 kB
Formato
Adobe PDF
|
325.08 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
